An isolated recombinant soluble endothelial cell protein C receptor (r-sEPCR) for use as a hemostatic agent.

An isolated recombinant soluble endothelial cell protein C receptor (r-sEPCR) for use as a hemostatic agent.

The invention relates to a linear polyglycerol compound, comprising a backbone of linearly linked glycerol residues. This compound is characterized in that it carries a plurality of substituents in the nature of covalently bound sulfates, wherein a degree of substitution of the backbone is preferably between 30 and 100%. A method of manufacturing the compound as well as uses of this compound and similar compounds are also disclosed.

The invention relates to a linear polyglycerol compound, comprising a backbone of linearly linked glycerol residues. This compound is characterized in that it carries a plurality of substituents in the nature of covalently bound sulfates, wherein a degree of substitution of the backbone is preferably between 30 and 100%. A method of manufacturing the compound as well as uses of this compound and similar compounds are also disclosed.

Factor IX/IXa variants and methods of use thereof are disclosed.

The present invention provides therapeutic products with decreased fibrinolytic activity of t-PA-deficient and/or plasminogen-deficient blood products, as well as compositions, kits and methods using the same in treating bleeding associated with hereditary or acquired bleeding disorders. The invention further provides extracorporeal apparatus for blood or blood products Plasmapheresis aimed to prevent or treat bleeding disorders.

The present invention provides therapeutic products with decreased fibrinolytic activity of t-PA-deficient and/or plasminogen-deficient blood products, as well as compositions, kits and methods using the same in treating bleeding associated with hereditary or acquired bleeding disorders. The invention further provides extracorporeal apparatus for blood or blood products Plasmapheresis aimed to prevent or treat bleeding disorders.

Thrombomodulin functional domains for use in promoting osteoblast functions and bone healing. Methods for stimulating bone regeneration, bone augmentation, treating a bone loss, a bone disorder and/or treating a bone-related disorder are disclosed. The method comprises administering, to a subject in need thereof a therapeutically effective amount of (I); a biologically, active recombinant polypeptide comprising, an amino acid sequence that is at least 80% identical to domains 2 and 3 of human thrombomodulin (TMD23); (II): an isolated polypeptide comprising recombinant TMD23 (rTMD23) or a biologically active recombinant variant thereof; or recombinant TMD23 (rTMD23) or a biologically active recombinant variant thereof, wherein the polypeptide is free of or lacking amino acid residues from domains 4 and 5 of the human thrombomodulin, and further wherein the biologically active variant thereof comprises an amino acid sequence that is at least 80% identical to the TMD23.

A method for manufacturing a fibrinogen preparation from a fibrinogen containing source derived from blood plasma includes providing a liquid phase containing plasmatic fibrinogen; contacting the liquid phase with a cation exchange chromatography material under conditions resulting in binding of fibrinogen, wherein the liquid phase has a pH in the range of pH 5.6 to pH 7.0 which is near or above the pl of fibrinogen; optionally washing unbound compounds from the cation exchange chromatography material; and eluting the fibrinogen from the cation exchange material. The method is also suitable for reduction of von-Willebrand-factor.

The composition and method of the invention relate to dental implant or orthognathic implant, graft materials and platelet-rich fibrin (PRF) applications in the field of dental and jaw health. The invention particularly relates to a therapeutic composition comprising at least one anti-sclerostin antibody and at least one anti dickkopf-1 antibody in combination for increasing osseointegration and accelerating healing in dental implantation and bone volume augmentation in filling of insufficient bone sites, and methods of local administration thereof.